GlobeNewswire by notified

Decreased number of shares and votes in Kinnevik

Share

Kinnevik AB (publ) ("Kinnevik") today announced that as of 30 July 2021 the total number of shares in the company amounts to 277,920,565, and the total number of votes in the company amounts to 581,719,453.

The decrease is due to the redemption of 200,479 reclassifiable, sub-ordinated incentive shares held in treasury by Kinnevik and by former participants in Kinnevik’s long-term share incentive plans resolved by the 2019 and 2020 Annual General Meetings, respectively. During July Kinnevik also has reclassified 42,034 incentive shares of class D 2018, 100,172 incentive shares of class E 2018, and 100,172 incentive shares of class F 2018 held by participants in Kinnevik’s long-term share incentive plan resolved by the 2018 Annual General Meeting into 242,378 ordinary shares of class B, in accordance with Kinnevik’s articles of association adopted to implement Kinnevik’s 2018 long-term share incentive plan. As a result of this reclassification, the number of class B shares in Kinnevik has increased during July and amounts to 242,153,584.

As of 30 July 2021, the total number of shares in Kinnevik are divided into two classes of ordinary shares and eight classes of incentive shares as follows:

  • 33,755,432 ordinary shares of class A with ten votes each and 242,153,584 ordinary shares of class B with one vote each, and
  • 297,258 incentive shares of class G 2018, 40,658 incentive shares of class D 2019, 115,392 incentive shares of class E 2019, 115,392 incentive shares of class F 2019, 408,862 incentive shares of class G 2019, 54,992 incentive shares of class C1 2020, 315,780 incentive shares of class C2 2020, and 663,215 incentive shares of class D 2020, with one vote each.

This information is of such character, which Kinnevik AB (publ) shall disclose in accordance with the Financial Instruments Trading Act (Sw. lagen (1991:980) om handel med finansiella instrument). The information was distributed for disclosure, through the agency of the contact person set out below, at 08:00 CEST on 30 July 2021.

For further information, visit www.kinnevik.com or contact:

Torun Litzén, Director Investor Relations
Phone +46 (0)70 762 00 50
Email press@kinnevik.com

Kinnevik’s ambition is to be Europe’s leading listed growth investor, and we back the best digital companies for a reimagined everyday and to deliver significant returns. We understand complex and fast-changing consumer behaviours, and have a strong and expanding portfolio in healthtech, consumer services, foodtech and fintech. As a long-term investor, we strongly believe that investing in sustainable business models and diverse teams will bring the greatest returns for shareholders. We back our companies at every stage of their journey and invest in Europe, with a focus on the Nordics, and in the US. Kinnevik was founded in 1936 by the Stenbeck, Klingspor and von Horn families. Kinnevik’s shares are listed on Nasdaq Stockholm’s list for large cap companies under the ticker codes KINV A and KINV B.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting24.4.2024 16:00:00 CEST | Press release

Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data selected for rapid oral session presentation MCLA-145 as monotherapy or in combination with pembrolizumab in solid tumors initial interim clinical data selected for rapid oral session presentation MCLA-129 in NSCLC with c-MET exon 14 skipping mutations initial interim clinical data selected for poster presentation UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the acceptance of three abstracts for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois on May 31- June 4, 2024. Rapid oral presentation: Title: Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m

Correction to stock exchange release: Siili Solutions Plc: Business review, 1 January – 31 March 202424.4.2024 15:55:00 CEST | Press release

Correction to stock exchange release: Siili Solutions Plc: Business review, 1 January – 31 March 2024 Siili Solutions Plc Stock exchange release 24 April 2024 at 16:55 This is a correction to the stock exchange release published by Siili Solutions Plc on 24 April 2024 at 9:45 am by which the company published its business review for the period 1 January – 31 March 2024. In section “Key events for January-March” it was stated that “75% of Siili employees have completed a GenAI certificate”. The correct information is that “51% of Siili employees in Finland have completed a GenAI certificate”. In addition, in the CEO review it was stated that “By the end of March, 75% of Siili’s employees in Finland had achieved the first-level certification.” The completion percentage was incorrect and the correct information is that “By the end of March, 51% of Siili’s employees in Finland had achieved the first-level certification.” The corrected release is stated below as a whole and the revised repo

Wereldhave announces reappointment of Supervisory Board member Hein Brand at Annual General Meeting of Shareholders24.4.2024 15:31:42 CEST | Press release

Wereldhave is pleased to announce the reappointment of Mr. Hein Brand as member of the Supervisory Board, as approved by the Annual General Meeting of shareholders (AGM) of Wereldhave N.V. In his role as Vice President of the Supervisory Board and Chairman of the Audit Committee, Mr Brand will continue to provide valuable leadership and guidance to the company for a period of two years, ending at the Annual General Meeting in April 2026. Full voting results of the Annual General Meeting will be published on the Company website. Attachment PB CORP 24-04-2024 - Wereldhave AGM reappoints Mr Hein Brand as Supervisory Board member

Leadership Evolution: Zafin Announces Strategic CEO Transition to Propel Future Growth24.4.2024 15:15:00 CEST | Press release

Al Karim Somji to Transition Leadership to Charbel Safadi as Part of Zafin's Long-Term Success Strategy VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- Zafin, the leading provider of SaaS core modernization and transformation solutions for banks, today announced a strategic leadership transition that has been part of the company’s long-term success plan. After more than two decades of exemplary leadership, Al Karim Somji will step down as Chief Executive Officer of Zafin. He will continue to serve as an ongoing member of the Board of Directors. As a founder of the Company, Al Karim has been pivotal in shaping Zafin's success, leaving a lasting legacy of excellence and innovation. Under his stewardship, Zafin has experienced significant growth and success, reinforcing its status as a leader in global banking technology. As an active board member and substantial owner, Al Karim will provide essential insight and guidance to ensure a smooth leadership transition. His exten

RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership24.4.2024 15:00:00 CEST | Press release

LOS ANGELES and AMSTERDAM, April 24, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (Nasdaq: RENB), a trailblazer in AI-driven early cancer diagnostics and therapeutics, and Cyclomics, a leader in ultra-sensitive 4th generation multi-omics molecular biology, proudly announce a significant milestone in their collaboration. RenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics, further cementing their shared commitment to advancing state-of-the-art technologies in cancer diagnostics and treatment. Their combined relationships with Oxford Nanopore and Nvidia will further position RenovaroCube to be a leader in early cancer diagnostics and monitoring of treatment efficacy. Oxford Nanopore is a leader in sequencing technologies and Nvidia will provide vital super computing power and front edge software solutions such as Parabricks, BioNeMo, Monai and Nemo. Initially set at a 75% acquisition, this decision to acquire the remaining 25% of Cy

HiddenA line styled icon from Orion Icon Library.Eye